AR
Arvinas, Inc.
ARVN · NASDAQ
$9.39 +0.86% (+$0.08)
1M +4.45%
Market Cap $605.9M
P/E Ratio 65.15x
Div. Yield -
ROE 1.91%
Piotroski F-Score Moderate
6/9Valuation
27 /100
Expensive P/E 65.15x
EV/EBITDA 179.16x
P/S 1.91x
Growth
78 /100
Growing Rev. growth 25.96%
Book val. growth 8.43%
EPS growth N/A
Profitability
25 /100
Weak Gross margin 96.43%
Net margin 2.94%
Op. margin 4.45%
Quality
10 /100
Poor ROIC 2.18%
ROE 1.91%
ROA 1.38%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 7.91x
Net debt/EBITDA -29.76x
Stability
17 /100
Unstable Beta 1.74x
Rev. volatility 149.04%
EPS volatility 46.61%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o ARVN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Randy Teel
Employees
246
Headquarters
New Haven
Nadchodzące wydarzenia
04 LIS
Earnings
Upcoming earnings report